Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 Mean change in Borg dyspnea index from baseline to week 12 in all patients (ALL), in patients with primary pulmonary hypertension (PPH) and in patients with associated forms of pulmonary hypertension (APH). Analysis of covariance adjusted by baseline values showed that Borg dyspnea index improved (decreased) in patients who received beraprost (solid bars) and worsened (increased) in the placebo group (open bars) over 12 weeks in ALL (p = 0.009) and in PPH patients (p = 0.013). No statistically significant changes were observed in APH patients (p = 0.935). Numbers at the tops of the bars = exact mean rates; lines = standard error of the mean. N = the number of patients in each group.
|
